Yuze Yang1, Stacy Ward-Charlerie1, Nitu Kashyap2, Richelle DeMayo3, Thomas Agresta4,5,6, James Green1. 1. Surescripts LLC, Arlington, Virginia, USA. 2. Clinical Informatics, Yale New Haven Health System, New Haven, Connecticut, USA. 3. Connecticut Children's Medical Center, Hartford, Connecticut, USA. 4. Clinical Informatics, Farmington, Connecticut, USA. 5. Connecticut Institute for Primary Care Innovation, Hartford, Connecticut, USA. 6. University of Connecticut, Storrs, Connecticut, USA.
Abstract
Objective: To illustrate the need for wider implementation of the CancelRx message by quantifying and characterizing the inappropriate usage of new electronic prescription (NewRx) messages for communicating discontinuation instructions to pharmacies. Materials and Methods: A retrospective analysis on a nationally representative random sample of 1 400 000 NewRx messages transmitted over 7 days to identify e-prescriptions containing medication discontinuation instructions in NewRx text fields. A vocabulary of search terms signifying cancellation instructions was formulated and then iteratively refined. True-positives were subsequently identified programmatically and through manual reviews. Two independent reviewers identified incidences in which these instructions were associated with high-alert or look-alike-sound-like (LASA) medications. Results: We identified 9735 (0.7% of the total) NewRx messages containing prescription cancellation instructions with 78.5% observed in the Notes field; 35.3% of identified NewRxs were associated with high-alert or LASA medications. The most prevalent cancellation instruction types were medication strength or dosage changes (39.3%) and alternative therapy replacement orders (39.0%). Discussion: While the incidence of prescribers using the NewRx to transmit cancellation instructions was low, their transmission in NewRx fields not intended to accommodate such information can produce significant potential patient safety concerns, such as duplicate or inaccurate therapies. These findings reveal the need for wider industry adoption of the CancelRx message by electronic health record (EHR) and pharmacy systems, along with clearer guidance and improved end-user training, particularly as states increasingly mandate electronic prescribing of controlled substances. Conclusion: Encouraging the use of CancelRx and reducing the misuse of NewRx fields would reduce workflow disruptions and unnecessary risks to patient safety.
Objective: To illustrate the need for wider implementation of the CancelRx message by quantifying and characterizing the inappropriate usage of new electronic prescription (NewRx) messages for communicating discontinuation instructions to pharmacies. Materials and Methods: A retrospective analysis on a nationally representative random sample of 1 400 000 NewRx messages transmitted over 7 days to identify e-prescriptions containing medication discontinuation instructions in NewRx text fields. A vocabulary of search terms signifying cancellation instructions was formulated and then iteratively refined. True-positives were subsequently identified programmatically and through manual reviews. Two independent reviewers identified incidences in which these instructions were associated with high-alert or look-alike-sound-like (LASA) medications. Results: We identified 9735 (0.7% of the total) NewRx messages containing prescription cancellation instructions with 78.5% observed in the Notes field; 35.3% of identified NewRxs were associated with high-alert or LASA medications. The most prevalent cancellation instruction types were medication strength or dosage changes (39.3%) and alternative therapy replacement orders (39.0%). Discussion: While the incidence of prescribers using the NewRx to transmit cancellation instructions was low, their transmission in NewRx fields not intended to accommodate such information can produce significant potential patient safety concerns, such as duplicate or inaccurate therapies. These findings reveal the need for wider industry adoption of the CancelRx message by electronic health record (EHR) and pharmacy systems, along with clearer guidance and improved end-user training, particularly as states increasingly mandate electronic prescribing of controlled substances. Conclusion: Encouraging the use of CancelRx and reducing the misuse of NewRx fields would reduce workflow disruptions and unnecessary risks to patient safety.
Authors: Basit Chaudhry; Jerome Wang; Shinyi Wu; Margaret Maglione; Walter Mojica; Elizabeth Roth; Sally C Morton; Paul G Shekelle Journal: Ann Intern Med Date: 2006-04-11 Impact factor: 25.391
Authors: Emily Beth Devine; Jennifer L Wilson-Norton; Nathan M Lawless; Ryan N Hansen; Thomas K Hazlet; Kerry Kelly; William Hollingworth; David K Blough; Sean D Sullivan Journal: Am J Health Syst Pharm Date: 2007-05-15 Impact factor: 2.637
Authors: Michael A Fischer; Christine Vogeli; Margaret Stedman; Timothy Ferris; M Alan Brookhart; Joel S Weissman Journal: Arch Intern Med Date: 2008-12-08
Authors: Melinda Beeuwkes Buntin; Matthew F Burke; Michael C Hoaglin; David Blumenthal Journal: Health Aff (Millwood) Date: 2011-03 Impact factor: 6.301
Authors: Ross Koppel; Joshua P Metlay; Abigail Cohen; Brian Abaluck; A Russell Localio; Stephen E Kimmel; Brian L Strom Journal: JAMA Date: 2005-03-09 Impact factor: 56.272
Authors: Samantha I Pitts; Noah Barasch; Andrew T Maslen; Bridgette A Thomas; Leonard P Dorissaint; Krista G Decker; Sadaf Kazi; Yushi Yang; Allen R Chen Journal: Appl Clin Inform Date: 2019-05-22 Impact factor: 2.342
Authors: Taylor L Watterson; Jamie A Stone; Roger Brown; Ka Z Xiong; Anthony Schiefelbein; Edmond Ramly; Peter Kleinschmidt; Michael Semanik; Lauren Craddock; Samantha Pitts; Taylor Woodroof; Michelle A Chui Journal: J Am Med Inform Assoc Date: 2021-07-14 Impact factor: 4.497
Authors: Taylor L Watterson; Jamie A Stone; Aaron Gilson; Roger Brown; Ka Z Xiong; Anthony Schiefelbein; Edmond Ramly; Peter Kleinschmidt; Michael Semanik; Lauren Craddock; Samantha I Pitts; Taylor Woodroof; Michelle A Chui Journal: BMC Med Inform Decis Mak Date: 2022-02-25 Impact factor: 2.796